Evidence map›Paper›PMID 36804871›Full record

ArticleJournal of acquired immune deficiency syndromes (1999)2023

Trajectories of Antiretroviral Therapy Adherence and Virologic Failure in Women With HIV in the United States.

Abubaker Ibrahim Elbur, Musie Ghebremichael, Deborah Konkle-Parker, Deborah L Jones, Shelby Collins, Adaora A Adimora, Michael F Schneider, Mardge H Cohen, Bani Tamraz, Michael Plankey and 4 more

Open access · hybridAbstract read
In one paragraph

Article in Journal of acquired immune deficiency syndromes (1999), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.4field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors at 13 institutions in 1 country.

Abubaker Ibrahim ElburCenter for Global Health, Massachusetts General Hospital, Boston, MA.
Musie GhebremichaelThe Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA.
Deborah Konkle-ParkerSchools of Nursing, Medicine and Population Health, University of Mississippi Medical Center, Jackson, MS.
Deborah L JonesDepartment of Psychiatry & Behavioral Sciences, University of Miami Miller School of Medicine, Miami, FL.
Shelby CollinsEmory University School of Medicine, Division of Infectious Disease, Atlanta, GA.
Adaora A AdimoraDepartment of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC.
Michael F SchneiderDepartment of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore.
Mardge H CohenDepartment of Medicine, Stroger Hospital of Cook County, Chicago IL.
Bani TamrazUniversity of California, San Francisco, School of Pharmacy, San Francisco, CA, MA.
Michael PlankeyGeorgetown University Medical Center, Department of Medicine, Division of General Internal Medicine, Washington DC.
Tracey WilsonSchool of Public Health, SUNY Downstate Health Sciences University, Brooklyn, NY.
Adebola AdedimejiDepartment of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, NY.
Jessica HabererCenter for Global Health, Massachusetts General Hospital, Boston, MA; and.
Denise L JacobsonCenter for Biostatistics in AIDS Research, Harvard T. H. Chan School of Public Health, Boston, MA.
Center for Global Health · USAlbert Einstein College of Medicine · USCancer Research And Biostatistics · USEmory University · USGeorgetown University Medical Center · USJohn H. Stroger, Jr. Hospital of Cook County · USJohns Hopkins University · USRagon Institute of MGH, MIT and Harvard · USSUNY Downstate Health Sciences University · USUniversity of California, San Francisco · USUniversity of Miami · USUniversity of Mississippi Medical Center · USUniversity of North Carolina at Chapel Hill · US

Funding

UCLA Clinical Translational Science InstituteUL1TR001881 · NCATS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ARLEEN F. BROWN, ARASH NAEIM · 2016 to 2026
$118.1M
The impact of HIV viral diversity and cellular immunity on HIV pathogenesisP30AI060354 · NIAID · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI ARTHUR Y KIM · 2004 to 2026
$94.4M
Virology CoreP30AI027767 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Paul A. Goepfert · 1988 to 2026
$84.1M
Engaging University of California Stakeholders for Biorespository ResearchUL1TR000004 · NCATS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI GRANDIS, JENNIFER RUBIN · 2012 to 2015
$78.0M
Virology, Immunology, and Microbiology CoreP30AI050410 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI DAVID M. MARGOLIS · 2001 to 2026
$76.9M
Virology and Molecular Biomarkers CoreP30AI050409 · NIAID · EMORY UNIVERSITY · PI Ann M Chahroudi, Colleen F Kelley · 2002 to 2026
$74.0M
QAQC Johns Hopkins Institute for Clinical and Translational ResearchUL1TR003098 · NCATS · JOHNS HOPKINS UNIVERSITY · PI FORD, DANIEL ERNEST · 2019 to 2023
$57.7M
SF Bay Area MACS/WIHS Combined Cohort StudyU01HL146242 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Bradley E Aouizerat, Jennifer Cohen Price · 2019 to 2026
$36.3M
Sex differences in the role of multi-omicsin HIV-associated carotid artery atherosclerosisU01HL146193 · NHLBI · JOHNS HOPKINS UNIVERSITY · PI Stephen J Gange, Elizabeth Topper · 2019 to 2026
$35.8M
University of Miami Developmental Center for AIDS Research (D-CFAR)P30AI073961 · NIAID · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI Savita Pahwa · 2007 to 2026
$33.8M
Clinical Research Sites for the MACS/WIHS Combined Cohort Study (MACS/WIHS-CCS) - Baltimore/Wash DC Center - Admin Supplement: Vision and dual sensory loss in HIV-infected older adultsU01HL146201 · NHLBI · JOHNS HOPKINS UNIVERSITY · PI TODD T BROWN, Joseph B. Margolick · 2019 to 2026
$33.7M
Sex differences in the role of multi-omics in HIV-associated carotid artery atherosclerosisU01HL146204 · NHLBI · ALBERT EINSTEIN COLLEGE OF MEDICINE · PI David B. Hanna, Anjali Sharma · 2019 to 2026
$33.2M
NCATS NIH HHS UL1 TR000004NCATS NIH HHS UL1 TR001881NCATS NIH HHS UL1 TR003098NHLBI NIH HHS U01 HL146192NHLBI NIH HHS U01 HL146193NHLBI NIH HHS U01 HL146194NHLBI NIH HHS U01 HL146201NHLBI NIH HHS U01 HL146202NHLBI NIH HHS U01 HL146203NHLBI NIH HHS U01 HL146204NHLBI NIH HHS U01 HL146205NHLBI NIH HHS U01 HL146241NHLBI NIH HHS U01 HL146242NHLBI NIH HHS U01 HL146245NIAID NIH HHS P30 AI027767NIAID NIH HHS P30 AI050409NIAID NIH HHS P30 AI050410NIAID NIH HHS P30 AI060354NIAID NIH HHS P30 AI073961NIAID NIH HHS T32 AI007433NIA NIH HHS U54 AG062334NIMH NIH HHS K24 MH114732NIMH NIH HHS P30 MH116867NIMH NIH HHS P30 MH133399
6 · The paper itself

Abstract

backgroundWomen with HIV (WHIV) in the United States face many challenges with adherence to antiretroviral therapy (ART), and suboptimal adherence often leads to virologic failure. This study aimed to determine the association between ART adherence trajectories and the risk of virologic failure.

methodsWe included WHIV (aged 18 years or older) enrolled in the Women's Interagency HIV Study in the United States from April 2014 to September 2019 who had at least 2 consecutive measurements of HIV RNA and ≥3 measurements of self-reported adherence. Group-based trajectory modeling was used to identify adherence trajectories. Cox proportional hazard ratios were used to measure the association.

main outcome measureVirologic failure was defined as HIV RNA ≥200 copies/mL at 2 consecutive visits.

resultsWe included 1437 WHIV (median age 49 years). Of all women, 173 (12.0%) experienced virologic failure. Four adherence trajectories were identified, namely "consistently high" (26.3%), "moderate increasing" (9.5%), "moderate decreasing" (30.6%), and "consistently low" (33.5%). Women in the consistently low adherence group consumed alcohol and experienced depression more than other groups. Compared with the "consistently high" trajectory, the risk of virologic failure was higher among women with "consistently low" [adjusted hazard ratio (aHR) 2.8; 95% confidence interval (CI): 1.6 to 4.9; P < 0.001] and "moderate decreasing" adherence trajectories (aHR 1.8; 95% CI: 1.0 to 3.2; P = 0.04), but it was similar to those with "moderate increasing" adherence trajectory (aHR 1.0; 95% CI: 0.4 to 2.5; P = 0.94).

conclusionsAdherence to ART remains a challenge among WHIV. Multilevel behavioral interventions to address poor adherence, alcohol consumption, and depression are needed.

Indexed as

Anti-HIV AgentsHIV InfectionsAnti-Retroviral AgentsAntiretroviral Therapy, Highly ActiveFemaleHumansMedication AdherenceMiddle AgedUnited StatesViral LoadAnti-HIV AgentsAnti-Retroviral Agents

Identifiers

PMID36804871
PMCPMC10180014
OpenAlexW4321366808

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.